Sermorelin 5mg
Sermorelin (GHRH 1-29) is a truncated analog of endogenous growth hormone-releasing hormone retaining full biological activity. It was FDA-approved for diagnostic evaluation and treatment of GH deficiency in children (Geref). Research demonstrates physiological GH secretion stimulation with preserved pulsatile release patterns.
Sequence
Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg
Market avg: $54.99 — save 36%
Volume pricing
Pay with USDC via Coinbase Commerce
Certificate of Analysis
Independently verified by Janoshik Analytical
Test ID
JAN-SERM-2026-001
Purity
99%
Method
HPLC-MS
Batch
SERM-2026-01A
Test Date
February 1, 2026
Identity
Confirmed
Endotoxin
<0.5 EU/mg
Storage Requirements
Lyophilized
2-8°C, protect from light
Reconstituted
2-8°C, use within 14 days
GHRH(1-29) analog. More temperature-sensitive than GHRPs. Refrigerate.
Published Research
2 peer-reviewed studies
GH-releasing peptides — structure and kinetics
Camanni F, Ghigo E, Arvat E. — Journal of Endocrinological Investigation, 1998
Analysis of GHRH analogs including sermorelin and their GH stimulation profiles.
Thirty years of human growth hormone-releasing hormone: from basic science to clinical use
Frohman LA, Kineman RD. — Endocrine Reviews, 2002
Comprehensive review of GHRH biology and clinical applications including sermorelin.
Related Products
CJC-1295 no DAC 2mg
GHRP-6 5mg
Ipamorelin 5mg
CJC-1295 with DAC 5mg
CJC-1295 + Ipamorelin Blend 10mg
GHRP-2 5mg
Hexarelin 2mg
Tesamorelin 5mg
Kisspeptin-10 5mg
Research use only. All products are sold strictly for in-vitro research purposes only. Not for human consumption. Information provided references published research literature. No medical claims are made or implied.